Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

12.56
HKD
-0.04
(-0.32%)
1.33EPS
10.27P/E
39.11BMarket Cap
Mar 12Next Earn
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A
HKEX:874
(Hong Kong Exchange)

Recent

price

12.56

P/E

ratio

10.27

div

yld

7.56%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.06
3.72
5.29
7.63
8.06
8.19
7.9
7.13
14.37
22.1
20.99
23.49
24.09
25.7
25.52
47.77
39.98
Revenue per Share
0.18
0.2
0.32
0.42
0.51
0.56
0.59
0.7
1.17
1.08
0.99
1.27
1.35
1.38
0.96
1.83
1.11
Basic EPS, GAAP
-0.01
-0.16
0.36
0.43
0.6
0.61
0.91
0.56
1.61
0.89
-0.1
1.5
1.91
0.84
0.79
-0.91
- -
Free Cash Flow per Basic Share
0.03
0.03
0.07
0.02
0.18
0.17
0.2
0.16
0.3
0.36
0.44
0.43
0.51
0.54
0.77
1.01
0.81
Dividend per Share
2.41
2.58
3.8
2.93
3.3
3.62
5.9
6.42
7.38
8.23
8.9
9.89
10.91
11.88
12.22
12.86
13.28
Book Value per Share
2.35
2.51
3.59
2.77
3.13
3.39
5.67
6.17
6.75
7.1
7.78
8.73
9.67
10.51
10.85
11.49
11.89
Tangible Book Value per Share
1,467
1,464
2,280
2,306
2,333
2,334
2,536
2,939
2,939
2,939
2,939
2,939
2,938
2,938
2,939
1,626
1,954
Basic Weighted Avg Shares
4,486
5,440
12,063
17,608
18,818
19,125
20,036
20,954
42,234
64,952
61,674
69,014
70,788
75,515
74,993
77,656
78,126
Sales/Revenue/Turnover
3.91
2.97
5.5
5.34
6.6
6.34
5.84
9.23
6.3
6.25
5.64
6.35
6.42
6.45
5.03
4.56
3.45
Operating Margin (%)
110
108
182
182
197
218
236
245
301
592
644
677
744
929
875
895
- -
Depreciation Expense
267
288
729
980
1,194
1,300
1,508
2,062
3,441
3,189
2,915
3,720
3,967
4,056
2,835
2,983
2,165
Net Income, GAAP
14.72
10.45
12.98
18.08
17.47
17.37
19.86
15.01
12.07
16.65
17.32
15.97
15.66
16.66
16.82
17.05
17.15
Effective Tax Rate (%)
5.95
5.29
6.04
5.57
6.35
6.8
7.53
9.84
8.15
4.91
4.73
5.39
5.6
5.37
3.78
3.84
2.77
Profit Margin (%)
1,462
1,441
1,877
2,249
2,839
2,976
12,092
13,231
15,943
16,605
18,153
20,557
19,669
19,748
18,847
22,394
24,220
Working Capital
4
4
24
9
22
40
34
35
1,014
551
1,059
1,251
2,185
3,902
3,251
3,545
6,190
LT Debt
3,642
3,895
5,756
7,022
7,922
8,684
17,654
19,259
23,144
25,989
28,205
31,327
33,638
36,678
37,770
40,083
41,400
Total Equity
7.11
7.12
13.96
12.64
13.38
12.95
8.58
11.08
13.27
10.63
8.66
10.24
9.97
9.16
6.01
5.67
3.79
Return on Invested Capital (%)
7.33
7.25
13.36
14.14
15.01
14.44
10.89
10.85
14.28
10.36
8.63
9.67
9.37
9.02
6.02
6.05
4.21
Return on Capital (%)
7.81
7.85
15.6
15.81
16.43
16.1
11.69
11.39
16.97
13.9
11.58
13.48
12.98
12.11
8.01
8.1
5.64
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
13,222
14,051
12,862
LT Borrowings
4,859
5,086
5,815
LT Finance Leases
367
405
375
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,939
2,939
2,939
Market Capitalization
43,313
36,129
33,422

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
65,065
64,381
61,984
Cash, Cash Equivalents & STI
12,332
13,289
11,903
Accounts Receivable, Net
19,895
18,974
19,867
Inventories
12,469
12,094
12,206
Total Current Liabilities
40,763
38,979
37,764
Payables & Accruals
- -
- -
- -
ST Debt
13,222
14,051
12,862
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19%
7.32%
6.12%
Free Cash Flow
-174.9%
-363.14%
-163.62%
Net Income, GAAP
11.53%
2.32%
5.21%
Sales/Revenue/Turnover
18.36%
4.8%
3.55%
Total Cash Common Dividend
18.68%
7.48%
-26.8%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,946
18,097
18,017
15,933
74,993
2025
22,473
19,361
- -
16,050
77,656
2026
23,278
18,813
19,985
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.67
0.36
0.37
-0.2
0.96
2025
0.62
0.43
- -
-0.2
1.83
2026
0.61
0.19
0.24
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.7
0.16
0.47
0.77
2025
0.03
0.4
- -
0.06
1.01
2026
0.03
0.45
0.41
- -
- -
Business
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures and sells Chinese patent medicines and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates; offers wholesale, retail, import and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical equipment and healthcare products; produces and sells beverages, food, healthcare products, pre-packaged food and dairy products including herbal tea, tablets, capsules, lozenges and tortoise herb jelly; and invests in health industries such as medical services, health management and healthcare. Key products include Xiaochaihu granules; kidney nourishing and fetal nourishing pills; Qingkailing series; thirst quenching pills; Huatuo Zaizao pills; honey chuanbei loquat cream; angong beef yellow pills; Xia Sangju series; compound salvia tablets series; banyan root granule series; compound banyan root granule series; Daishen Stomach Qingqing granule series; snake tan chuanbei loquat cream; sildenafil citrate (Jinfengo); cefuroxime sodium for injection; acafol powder; multivitamin injection (12); amoxicillin; cefixime series; amoxicillin clavulanate potassium; clindamycin phosphate injection; mosapride citrate capsules; cefminox sodium; cefpiramide; cefprozil; Wanglaoji herbal tea; tangerine series; Li Xiaoji series; coconut milk; and throat lozenges. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments and serves markets in the People's Republic of China and internationally, primarily targeting pharmaceutical wholesalers, retailers, hospitals and consumers. Founded in 1997 and headquartered in Guangzhou, China, it functions as a key subsidiary of Guangzhou Pharmaceutical Group under China National Pharmaceutical Group (Sinopharm). In September 2025, its controlled partnership GP Fund II acquired an 11.04% equity interest in a target company for RMB 748.8 million to strengthen strategic cooperation, classified as a disclosable transaction under Hong Kong Listing Rules. Recent activities also encompass completion of recruitment fund projects with surplus funds allocated to working capital and initiation of accounts receivable securitization by subsidiaries.